Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma
•We provide a recommendation for the treatment of multi-hit MM.•Lenalidomide has an advantage in improving the early ORR of multi-hit MM.•Tandem-ASCT can further prolong the long-term survival rate of multi-hit MM.•We analyzed factors affecting survival of MM with and without ASCT by univariate and...
Gespeichert in:
Veröffentlicht in: | Leukemia research 2021-11, Vol.110, p.106710-106710, Article 106710 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •We provide a recommendation for the treatment of multi-hit MM.•Lenalidomide has an advantage in improving the early ORR of multi-hit MM.•Tandem-ASCT can further prolong the long-term survival rate of multi-hit MM.•We analyzed factors affecting survival of MM with and without ASCT by univariate and multivariate analyses.
In order to investigate the efficacy of lenalidomide, bortezomib and dexamethasone (VRD) induction chemotherapy regimen combined with tandem autologous stem cell transplantation (ASCT) in treating multi-hit multiple myeloma (MM), we analyzed 252 cases of newly diagnosed MM treated with the bortezomib-containing induction chemotherapy from June 2016 to June 2019. According to the fluorescence in situ hybridization (FISH) results on diagnosis, the patients were divided into multi-hit MM group (47 cases), single-hit MM group (81 cases), and standard-risk group (124 cases). Our analysis showed that R-ISS stageⅢ in transplantation group and R-ISS stageⅢ, multi-hit and VGPR or above was not achieved at the fourth cycle of chemotherapy in non-transplantation group were independent factors for poor prognosis by univariate and multivariate analyses. Moreover, the overall response rate (ORR) of VRD induction chemotherapy group was significantly higher than that of the non-VRD group in the single-hit and multi-hit groups (P = 0.021, P = 0.032); In terms of ASCT, tandem-ASCT can significantly improve the 2-year PFS (77.8 ± 3.9 %) and OS (83.3 ± 5.6 %) of multi-hit MM (P = 0.024, P = 0.037), while single-ASCT only has a limited effect on PFS (61.5 ± 3.0 %) and OS (71.9 ± 4.5 %) (P = 0.115, P = 0.155). |
---|---|
ISSN: | 0145-2126 1873-5835 |
DOI: | 10.1016/j.leukres.2021.106710 |